Lucas Michon

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan et al. · Journal for ImmunoTherapy of Cancer · 2022 · 69 citations · Full text

Medicine, Immunology, Oncology +17

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Jean‐Philippe Foy, Andy Karabajakian, Sandra Ortiz‐Cuaran et al. · European Journal of Cancer · 2022 · 66 citations

Life Sciences, Immunology, Oncology +17

Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival

Jebrane Bouaoud, Jean‐Philippe Foy, Antonin Tortereau et al. · OncoImmunology · 2021 · 37 citations · Full text

Medicine, Immunology, Oncology +17

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Andy Karabajakian, Jebrane Bouaoud, Lucas Michon et al. · Oral Oncology · 2021 · 34 citations · Full text

Medicine, Oncology, Pathology +17

Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer

Sandra Ortiz‐Cuaran, Aurélie Swalduz, Jean‐Philippe Foy et al. · European Journal of Cancer · 2022 · 32 citations

Medicine, Immunology, Oncology +14